HER2-TTC, a thorium-227-labeled HER2-targeting alpha therapeutic, induced cytotoxicity and cell cycle arrest in HER2-positive cancer cells in vitro and induced the formation of DSBs both in vitro and in vivo. The gene discussed is ERBB2; the disease is cancer.